welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Solid Biosciences Provides SGT-001 Program Update


CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) today provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration (FDA) has notified the company that IGNITE DMD, its Phase I/II study of SGT-001, has been placed on clinical hold. The company will hold a webcast conference call this morning to discuss this update.

To date, six patients have been dosed with SGT-001, Solid’s gene transfer candidate under investigation for Duchenne muscular dystrophy (DMD). This includes three patients in the first cohort at a 5E13 vg/kg dose, who continue to do well and are being followed per the study protocol. Three patients were subsequently dosed in the second cohort at a 2E14 vg/kg dose. The first two of these patients are also doing well and being followed per study protocol.

Solid Biosciences Provides SGT-001 Program Update